Luxturna

Spark Therapeutics Inc (NASDAQ: ONCE), a gene therapy company that treats orphan diseases including a rare retinal disease that can lead to blindness, said in early January it will price its therapy at $850,000 for a one-time treatment of both eyes. The Analyst Wedbush's David Nierengarten...

The first gene therapy treatment ever approved in the U.S. comes with a steep price tag. On Wednesday, Spark Therapeutics Inc (NASDAQ: ONCE) announced it will charge $425,000 per eye for one-time treatments of a rare genetic retinal disease that causes blindness. The new therapy could be a huge...

Spark Therapeutics Inc (NASDAQ: ONCE) saw its name transition from Wall Street headlines to Main Street headlines after a U.S. Food and Drug Administration voted favorably on the company's therapy. Spark develops a gene therapy treatment called Luxturna for a rare inherited blindness disease,...

On Thursday afternoon, and FDA advisory panel recommended approval of Spark Therapeutics Inc (NASDAQ: ONCE)’s Luxturna treatment for inherited blindness. A number of Wall Street analysts weighed in on the stock following the news. Here’s an overview of what they had to say. Voices...

Analysts at Jefferies hosted a fireside chat-themed conversation with Spark Therapeutics Inc (NASDAQ: ONCE) to discuss the company's successes from Thursday's FDA panel. Analyst Michael Yee maintains a Buy rating on Spark's stock with an unchanged $95 price target and noted three main...

Analysts at Cantor Fitzgerald continue to hold a bullish stance on Spark Therapeutics Inc (NASDAQ: ONCE) after the U.S. Food and Drug Administration gave the company a critical recommendation for its therapy called Luxturna. Analyst Elemer Piros maintains an Overweight rating on Spark's stock...